Anti-Coagulants - South America

South America

In South America, the revenue in the Anti-Coagulants market is estimated to reach US$0.94bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 7.82%, leading to a market volume of US$1.37bn by 2029.
When compared globally, United States is projected to generate the highest revenue of US$16,740.00m in 2024.
In South America, there is a growing demand for novel oral anticoagulants as a more convenient and effective alternative to traditional anticoagulant therapies.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in South America has been experiencing steady growth in recent years.

Customer preferences: The increasing prevalence of cardiovascular diseases has led to a rise in demand for anti-coagulants in South America. Patients with atrial fibrillation and deep vein thrombosis require anti-coagulants to prevent blood clots and reduce the risk of stroke. As a result, there has been a growing preference for direct oral anti-coagulants (DOACs) over traditional anti-coagulants like warfarin due to their convenience and ease of use.

Trends in the market: Brazil is the largest market for anti-coagulants in South America, accounting for a significant portion of the region's total revenue. The country's aging population, coupled with the high prevalence of cardiovascular diseases, has contributed to the growth of the anti-coagulants market in Brazil. In addition, increased government spending on healthcare has led to improved access to medical care, which has further fueled the demand for anti-coagulants.Argentina and Chile are also emerging markets for anti-coagulants in South America. Both countries have witnessed a rise in the number of patients with cardiovascular diseases, leading to an increase in demand for anti-coagulants. The availability of novel oral anti-coagulants (NOACs) has also contributed to the growth of the anti-coagulants market in these countries.

Local special circumstances: In Brazil, the government's "Farmácia Popular" program has made anti-coagulants more affordable and accessible to patients. The program provides free or subsidized medication to low-income individuals, which has led to an increase in the number of patients seeking treatment for cardiovascular diseases.In Argentina, the government has implemented price controls on pharmaceutical products, which has led to a decrease in the price of anti-coagulants. This has made the medication more affordable for patients, leading to an increase in demand.

Underlying macroeconomic factors: The growing economies of South America have led to an increase in healthcare spending, which has fueled the growth of the anti-coagulants market. In addition, the region's aging population and increasing prevalence of cardiovascular diseases have contributed to the rising demand for anti-coagulants.Overall, the Anti-Coagulants market in South America is expected to continue its growth trajectory in the coming years, driven by increasing demand for DOACs and NOACs, government initiatives to improve healthcare access, and the region's favorable macroeconomic conditions.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.